4/9
08:00 am
nams
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
Low
Report
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
4/9
08:00 am
nams
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Low
Report
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
4/1
08:19 am
nams
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer [Yahoo! Finance]
High
Report
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer [Yahoo! Finance]
4/1
08:00 am
nams
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
High
Report
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
3/25
08:00 am
nams
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
Low
Report
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
3/14
08:08 am
nams
NewAmsterdam Pharma (NASDAQ: NAMS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $35.00 price target on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ: NAMS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $35.00 price target on the stock.
3/12
08:00 am
nams
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
High
Report
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
2/29
12:33 pm
nams
NewAmsterdam Pharma (NASDAQ: NAMS) had its price target raised by analysts at Royal Bank of Canada from $25.00 to $31.00. They now have an "outperform" rating on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ: NAMS) had its price target raised by analysts at Royal Bank of Canada from $25.00 to $31.00. They now have an "outperform" rating on the stock.
2/28
08:00 am
nams
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
2/26
08:00 am
nams
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
Medium
Report
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
2/13
10:40 pm
nams
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Low
Report
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
2/13
04:01 pm
nams
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Low
Report
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
2/1
04:01 pm
nams
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Medium
Report
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference